Examining TGF β 1 Gene Variations in Leprosy Patients
TGF β 1 Expression Related Gene Polymorphism and Their Association With Clinical Types of Leprosy
This study is trying to see how different versions of a gene related to the immune system affect people with leprosy and their treatment outcomes.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 60 (estimated) |
| Ages | 18 Years to 50 Years |
| Sex | All |
| Sponsor | Aswan University Academic / other |
| Locations | 1 site (Aswān) |
| Trial ID | NCT06683690 on ClinicalTrials.gov |
What this trial studies
This observational study investigates the expression of TGF β 1 gene polymorphisms in patients diagnosed with leprosy, a chronic infectious disease caused by Mycobacterium leprae. The research aims to understand how variations in this gene may influence the immune response and clinical manifestations of leprosy, which can range from mild skin lesions to severe nerve damage. By measuring TGF β 1 levels in patients undergoing multidrug therapy, the study seeks to elucidate the role of this cytokine in the disease's progression and healing processes.
Who should consider this trial
Good fit: Ideal candidates for this study are adults over 18 years old diagnosed with leprosy who are currently receiving multidrug therapy.
Not a fit: Patients with other dermatological diseases, leprosy reactions, autoimmune diseases, or those who are pregnant or lactating may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance understanding of leprosy's immune response, potentially leading to improved treatment strategies.
How similar studies have performed: While there is limited research specifically on TGF β 1 in leprosy, studies on cytokine expression in infectious diseases have shown promising results, suggesting potential for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients of both sexes with leprosy. * Age above 18 years. * patients on multidrug therapy of leprosy. Exclusion Criteria: * Patients with other dermatological disease. * Patients with leprosy reaction. * Pregnancy and lactation. * Patients with autoimmune disease.
Where this trial is running
Aswān
- Aswan Universit Hospital — Aswān, Egypt (Recruiting)
Study contacts
- Study coordinator: Gehad Adel Abd El-Sabour, M.D
- Email: gehada022@gmail.com
- Phone: +201000415446
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.